Shares of InfuSystem plunged 17.1% following a disappointing quarter marked by margin pressure and a cautious outlook, despite reported pro forma revenue growth that failed to offset concerns over contract restructuring and segment declines.

• Reported Q1 revenue declined 3% year-over-year to $33.7 million, largely due to $1.6 million lower revenue from GE Healthcare contract restructuring.
• On a pro forma basis excluding the restructuring impact, revenue grew 1.7%, driven by higher patient service revenues (+6.4%) including oncology (+2.4%) and wound care (~112% growth).
• Device Solutions revenue dropped 17%, primarily reflecting the loss of GE Healthcare contract revenue.
• Adjusted EBITDA was approximately $6.4 million, flat year-over-year, with a modest margin increase to 18.9%, but expected to remain in the low-to-mid 20% range partly due to IT upgrade costs.
• The ERP system implementation was a major milestone but initial post-go-live issues add uncertainty around near-term operational efficiencies.